

# Multidimensional Impact of Tardive Dyskinesia: Interim Analysis of Clinician-Reported Measures in the IMPACT-TD Registry

Stacy Finkbeiner,<sup>1</sup> Martijn Konings,<sup>1</sup> Mark Henegar,<sup>1</sup> James Bennett,<sup>2</sup> Carolyn Rainville,<sup>2</sup> Richard Jackson<sup>3</sup>

<sup>1</sup>Teva Branded Pharmaceutical Products R&D, Inc., Parsippany, NJ, United States; <sup>2</sup>Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, United States; <sup>3</sup>University of Michigan School of Medicine, Ann Arbor, MI, United States

Poster number: 34



## Objective: To assess the multidimensional impact of tardive dyskinesia on patients' lives using the clinician-reported measures of the IMPACT-TD Registry

### Background

- Tardive dyskinesia (TD) is a hyperkinetic movement disorder associated with dopamine receptor antagonist exposure<sup>1</sup>
- TD can negatively affect many aspects of a patient's quality of life and/or functioning,<sup>2,3</sup> but the multidimensional impact and burden of TD are not well understood
- Patient- and clinician-reported outcomes are important in determining the severity and multidimensional impact of TD on patients
  - The IMPACT-TD clinician scale is a newly developed clinician-reported outcome tool to assess the multidimensional impact of TD on patients' lives<sup>3</sup>

### Methods

- The IMPACT-TD Registry is an ongoing, real-world, phase 4, 3-year longitudinal study, with data collected approximately every 3 months<sup>4</sup>
  - Patients aged ≥18 years with a score of ≥2 on at least one item of the Abnormal Involuntary Movement Scale (AIMS) and probable TD or, alternatively, who are on vesicular monoamine transporter type 2 inhibitor (VMAT2i) therapy, were included
- For this interim analysis, based on 286 patients enrolled as of December 31, 2023, baseline data on the multidimensional impact of TD were measured using the IMPACT-TD clinician scale. More information on this scale is published in Jackson et al. (2022), *Journal of Clinical Psychiatry*<sup>3</sup>
  - A 4-point Likert scale allows clinicians to rate 4 functional domains by scoring them from 0 to 3 (Table 1)<sup>3</sup>
  - Social, psychological/psychiatric, physical, and vocational/educational/recreational domains are rated, with the highest impact in any domain considered the IMPACT-TD global score<sup>3</sup>
- Severity of TD movements was assessed using the Clinical Global Impression of Severity of TD (CGIS-TD) and total motor AIMS score

Table 1. Clinician IMPACT-TD Rating Score Options

0	1	2	3
No impact	Mild impact	Moderate impact	Severe impact
	Impact is present, but minimal	Exceeds minimal impact, but is not severe	Significant and detrimental impact

### Demographics

- Among the 286 patients enrolled at the time of the interim analysis, there was considerable ethnic and racial diversity (Table 2)

Table 2. Patient Demographics at Baseline

	N=286
Age, mean (SD), years	51.8 (14.5)
Sex, n (%)	
Male	142 (50)
Female	144 (50)
Race, n (%)	
White	159 (56)
Black or African American	63 (22)
Other or not reported	64 (22)
Ethnicity, n (%)	
Not Hispanic or Latino	199 (70)
Hispanic or Latino	75 (26)
Unknown or not reported	12 (4)
Current psychiatric comorbidities, n (%)	
Anxiety disorder	98 (34)
Bipolar disorder	117 (41)
Depression	98 (34)
Schizoaffective disorder	45 (16)
Schizophrenia	94 (33)
Any previous antipsychotic medication, n (%)	
First-generation antipsychotics only	17 (6)
Second-generation antipsychotics and beyond only	172 (60)
Both first- and second-generation antipsychotics and beyond	67 (23)
Not reported	29 (10)
Patients receiving concomitant VMAT2i treatment, n (%)	78 (27)

### Acknowledgments

Medical writing and editorial support were provided by Anneke Brand, PhD, Alison Adams, PhD, CMPP, and Kelsey Gribbon, MS, of Ashfield MedComms, an Inizio company, and were funded by Teva Branded Pharmaceutical Products R&D, Inc.

### Disclosures

This study was supported by Teva Branded Pharmaceutical Products R&D, Inc. Stacy Finkbeiner, Martijn Konings, Mark Henegar, James Bennett, and Carolyn Rainville are employees and shareholders of Teva Pharmaceuticals. Richard Jackson served as a consultant/speakers bureau participant for Teva Pharmaceuticals and has received payments from Teva Pharmaceuticals in relation to this study.

### Abbreviations

AIMS = Abnormal Involuntary Movement Scale, CGIS-TD = Clinical Global Impression of Severity of TD, TD = tardive dyskinesia, VMAT2i = vesicular monoamine transporter type 2 inhibitor.


### References

- Anderson K, et al. *Lancet Psychiatry*. 2017;4:595–605.
- McEvoy J, et al. *Qual Life Res*. 2019;28:3303–3312.
- Jackson R, et al. *J Clin Psychiatry*. 2022;84:22cs14563.
- Jackson R, et al. Poster presented at: the 28th Annual National Psychopharmacology Update; February 15–18, 2023; Las Vegas, NV.

## 98% of patients experience the impact of TD on some aspect of their life, and more than half of patients with mild TD experienced moderate to severe impact of TD

- Based on clinician assessment with IMPACT-TD (n=251), most patients (83%) experienced moderate to severe impact in at least 1 domain (IMPACT-TD global score, ≥2) (Figure 1)


Figure 1. Clinician-Reported Impact of TD in Domains of the IMPACT-TD Scale at Baseline



Percentage values indicate the percentage of patients within each domain experiencing mild to severe impact or moderate to severe impact, respectively.

- 54% and 61% of patients with very mild and mild TD severity on CGIS-TD, respectively, experienced moderate to severe impact on the clinician IMPACT-TD global score (Figure 2A)
  - In those with more severe movements, 90% of patients with moderate and 100% of patients with markedly severe and very severe TD movements on CGIS-TD experienced moderate to severe impact
- 74%, 88%, and 96% of patients with total motor AIMS scores of 1 to 6, 7 to 14, and ≥15, respectively, experienced moderate to severe impact (Figure 2B)

Figure 2. IMPACT-TD Global Scores in Patients Grouped Based on Their Severity of Movements at Baseline




Percentages do not sum to 100 due to rounding.

### Clinical characteristics

- TD severity at baseline according to total motor AIMS score varied across patients (Figure 3)
- Based on CGIS-TD at baseline (n=246), 1% of patients were classified as having no severity at all, 10% very mild severity, 23% as mild, 37% as moderate, 21% as markedly severe, and 8% as very severe; no patient was classified as having among the most severe TD seen

Figure 3. TD Severity Assessed by Total Motor AIMS Score at Baseline



Total motor AIMS score was calculated as the sum of items 1 to 7 (range for each item, 0 = none to 4 = severe).

### Additional results

- 73% of all patients (183/251) experienced moderate to severe impact in multiple domains of life as assessed by the clinician IMPACT-TD scale (Figure 4)

Figure 4. Number of IMPACT-TD Domains of Life in Which Patients Experienced Moderate or Severe Impact at Baseline

